What is poorly differentiated thyroid carcinoma?
Poorly differentiated thyroid carcinoma (PDTC) is an uncommon thyroid cancer that sits between the common, slow-growing thyroid cancers and the very aggressive anaplastic thyroid cancer. It accounts for only a few per cent of thyroid cancers, but it causes a large share of thyroid cancer deaths.
Like papillary and follicular thyroid cancers, PDTC grows from the follicular cells of the thyroid, the cells that make thyroid hormone. “Poorly differentiated” means the cancer cells have lost much of their normal structure and function. They grow in solid sheets, divide faster and are less able to take up iodine.
PDTC may arise on its own or develop within a long-standing papillary or follicular cancer. In the 2022 World Health Organization classification, it is grouped with differentiated high-grade thyroid carcinoma as one of the high-grade follicular cell-derived thyroid cancers.
It usually affects adults over 50 and often presents as a large thyroid lump, sometimes with spread to the lungs or bones. Treatment combines surgery, radioactive iodine when the tumour still takes it up, radiotherapy and, for advanced disease, targeted tablets (Tong et al., 2022).
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of cancer | High-grade thyroid cancer from follicular cells |
| How common | Uncommon; a few per cent of thyroid cancers, varying between countries |
| Typical age | Usually 50-70 |
| Sex | More common in women, but the gap is smaller than for papillary cancer |
| Typical presentation | Large, firm thyroid lump; spread beyond the thyroid is common |
| Common sites of spread | Neck lymph nodes, lungs, bone |
| Key gene changes | RAS, TERT promoter, BRAF, TP53 |
| Main treatment | Total thyroidectomy, radioactive iodine if taken up, radiotherapy, targeted drugs |
| Outlook | About 74% alive and 49% disease-free at 5 years in a pooled analysis |
2. Where PDTC fits among thyroid cancers
| Cancer | Growth speed | Iodine uptake | Typical outlook |
|---|---|---|---|
| Papillary thyroid cancer | Slow | Usually good | Excellent |
| Follicular thyroid cancer | Slow | Usually good | Very good |
| Poorly differentiated thyroid carcinoma | Moderate to fast | Often reduced | Intermediate |
| Differentiated high-grade thyroid carcinoma | Moderate to fast | Often reduced | Intermediate |
| Anaplastic thyroid cancer | Very fast | None | Poor |
3. Causes and risk factors
The exact cause of PDTC is not known. Risk factors are similar to those for thyroid cancer in general.
| Risk factor | Notes |
|---|---|
| Older age | Most patients are over 50 |
| Radiation exposure in childhood | A known cause of thyroid cancer |
| Long-standing goitre or iodine deficiency | PDTC appears more common in iodine-deficient regions |
| Pre-existing well-differentiated cancer | PDTC can develop within papillary or follicular cancer |
Gene changes
| Gene change | Approximate frequency | Notes |
|---|---|---|
| RAS mutations | Common | Typical of follicular-pattern tumours |
| TERT promoter mutations | Common | Linked with aggressive behaviour |
| BRAF V600E | Less common than in papillary cancer | A drug target when present |
| TP53 and other changes | Some tumours | Suggest progression towards anaplastic cancer |
| RET, NTRK or ALK fusions | Rare | Treatable with specific drugs |
These changes develop in the tumour cells. PDTC is not usually inherited (Xu and Ghossein, 2020).
4. How does it look
In the neck
| Feature | Description |
|---|---|
| Lump | A firm, often large thyroid nodule, usually over 3-4 cm |
| Growth | May enlarge over weeks to months |
| Fixation | Can feel fixed to surrounding tissues |
| Lymph nodes | Swollen neck glands in some people |
On scans
| Scan | Typical findings |
|---|---|
| Ultrasound | A solid, dark (hypoechoic) nodule, sometimes with irregular edges |
| CT or MRI | Shows the size of the tumour, spread outside the thyroid and involvement of the windpipe or gullet |
| Radioactive iodine scan | Often shows reduced or patchy uptake |
| FDG PET-CT | Often bright, reflecting high activity; useful when iodine scans are negative |
Under the microscope
Pathologists usually use the Turin criteria to diagnose PDTC (Asioli et al., 2010):
| Criterion | Description |
|---|---|
| Growth pattern | Solid, trabecular or insular (nest-like) growth |
| Nuclei | Lack the typical features of papillary cancer |
| Plus at least one of | Convoluted nuclei, 3 or more mitoses per 10 high-power fields, or tumour necrosis |
| Additional feature | Notes |
|---|---|
| Thyroglobulin stain | Often weaker or patchy |
| TTF-1 and PAX8 | Positive, confirming thyroid origin |
| Ki-67 | Higher than in well-differentiated cancers |
5. Symptoms
Some people have no symptoms apart from a lump. Others have symptoms caused by pressure on nearby structures.
Common symptoms
- A lump in the front of the neck that may grow over weeks or months
- Hoarseness or a change in voice
- Difficulty swallowing
- Breathlessness or noisy breathing, from pressure on the windpipe
- Swollen glands in the neck
- A feeling of pressure or tightness in the neck
Symptoms of spread
| Site | Possible symptoms |
|---|---|
| Lungs | Cough, breathlessness, chest pain, coughing blood |
| Bone | Bone pain, fracture, back pain |
| Brain | Headache, weakness, seizures (rare) |
Thyroid function
Most people with PDTC have normal thyroid hormone levels, so they do not notice symptoms of an overactive or underactive thyroid.
When to seek medical advice
See a doctor about a lump in the neck, especially if it is growing, hard, or linked with hoarseness, swallowing problems or breathlessness. Seek urgent care for difficulty breathing or noisy breathing.
6. Diagnosis
| Test | Purpose |
|---|---|
| Neck examination | Assesses the lump and lymph nodes |
| Thyroid ultrasound | Shows the nodule’s features and guides biopsy |
| Fine needle aspiration (FNA) or core biopsy | Takes cells for diagnosis; PDTC is often only fully confirmed after surgery |
| Blood tests | Thyroid function, thyroglobulin and calcitonin |
| Laryngoscopy | Checks the movement of the vocal cords |
| CT of the neck and chest | Assesses local extent and lung spread |
| FDG PET-CT | Detects spread, especially when iodine uptake is low |
| Molecular testing | Identifies BRAF, RET, NTRK and other targetable changes |
Staging
Thyroid cancers of follicular cell origin are staged with the TNM system, and age at diagnosis is part of the staging. People under 55 are classed as stage I unless there is distant spread, while older people are staged according to tumour size, spread outside the thyroid and lymph node involvement.
| Factor | Why it matters |
|---|---|
| Tumour size | Larger tumours behave worse |
| Extrathyroidal extension | Growth into the neck muscles, windpipe or nerves is a strong warning sign |
| Lymph node spread | Raises the risk of recurrence in the neck |
| Distant spread | Most often to the lungs and bones |
| Age | Outcomes are less favourable in older patients |
7. Treatment
Treatment is planned by a thyroid cancer multidisciplinary team, including endocrine surgeons, endocrinologists, nuclear medicine doctors and oncologists.
Surgery
| Operation | Notes |
|---|---|
| Total thyroidectomy | Removal of the whole thyroid; the standard operation |
| Central neck dissection | Removal of lymph nodes next to the thyroid |
| Lateral neck dissection | When lymph nodes at the side of the neck are involved |
| Extended surgery | When the tumour invades the windpipe, gullet or larynx |
Complete removal of all visible cancer is the most important factor for a good outcome.
Radioactive iodine (RAI)
After thyroidectomy, radioactive iodine is offered if the tumour still takes up iodine. Many PDTCs take up iodine weakly or not at all, so RAI helps some patients but not others. Uptake is checked on post-treatment scans.
Radioactive iodine treatment step by step
| Step | What happens |
|---|---|
| 1. Preparation | A low-iodine diet for 1-2 weeks and injections of recombinant TSH, or a short break from thyroid tablets |
| 2. Treatment | A capsule or drink of radioactive iodine, usually given during a short hospital stay |
| 3. Isolation | A few days in a single room, then limited close contact at home for a short period |
| 4. Scan | A whole-body scan a few days later shows where the iodine has gone |
| 5. Review | Blood tests and scans months later check whether the treatment worked |
What does iodine-refractory mean?
Normal thyroid cells, and many well-differentiated thyroid cancers, absorb iodine from the blood. This is why radioactive iodine can destroy them from the inside. Poorly differentiated cancers often lose this ability.
When a tumour does not take up iodine, or keeps growing despite it, doctors call it iodine-refractory. At that point, further iodine treatment is unlikely to help, and targeted drugs, radiotherapy or surgery become the main options.
External beam radiotherapy
Radiotherapy to the neck may be recommended when the cancer has grown outside the thyroid, when margins are positive, or when there is residual disease that does not take up iodine. It is also used to relieve pain from bone metastases.
Targeted drugs for advanced disease
| Drug | Target | Notes |
|---|---|---|
| Lenvatinib | Multiple kinases (VEGFR and others) | Standard first option for progressive iodine-refractory disease |
| Sorafenib | Multiple kinases | An alternative first-line option |
| Cabozantinib | Multiple kinases | After earlier treatment |
| Dabrafenib plus trametinib | BRAF V600E | For BRAF-mutated tumours |
| Selpercatinib or pralsetinib | RET fusions | For RET fusion-positive tumours |
| Larotrectinib or entrectinib | NTRK fusions | For NTRK fusion-positive tumours |
Side effects
| Treatment | Possible side effects |
|---|---|
| Thyroidectomy | Hoarse voice, low calcium, need for lifelong thyroid hormone tablets |
| Radioactive iodine | Dry mouth, taste changes, swelling of salivary glands |
| Radiotherapy | Sore throat, difficulty swallowing, skin changes, tiredness |
| Kinase inhibitors | High blood pressure, diarrhoea, tiredness, weight loss, hand-foot skin reaction, protein in the urine |
8. Outlook (prognosis)
| Measure | Pooled figure |
|---|---|
| 5-year overall survival | About 74% |
| 5-year disease-free survival | About 49% |
| Strongest risk factor | Spread of the cancer outside the thyroid (extrathyroidal extension) |
These figures come from a 2024 analysis of 20 studies and almost 1,300 patients treated with surgery (Kim et al., 2024). The outlook is best when the cancer is confined to the thyroid and completely removed. It is worse in older patients, with large tumours, distant spread at diagnosis or tumours that do not take up iodine.
9. Follow-up
| Follow-up | Purpose |
|---|---|
| Thyroglobulin blood tests | A rising level may suggest recurrence, although PDTC may make less thyroglobulin |
| Neck ultrasound | Detects recurrence in the neck |
| CT chest and PET-CT | For high-risk patients or rising tumour markers |
| Thyroid hormone dose checks | Keeps TSH at the target set by the team |
| Calcium and voice checks | After surgery |
10. Living with poorly differentiated thyroid carcinoma
- Take levothyroxine every day, ideally on an empty stomach at the same time each day
- Keep regular blood tests to check hormone levels and tumour markers
- Follow radiation safety advice after radioactive iodine treatment
- Manage side effects of targeted drugs with your team, including blood pressure checks
- Report new symptoms such as cough, bone pain or a new neck lump
- Carry a list of your medicines, including your levothyroxine dose, to every appointment
- Look after your voice with speech therapy if it has changed after surgery
- Seek support from thyroid cancer charities and patient groups
11. Frequently asked questions
| Question | Answer |
|---|---|
| Is PDTC the same as anaplastic thyroid cancer? | No. It is less aggressive, but more serious than papillary or follicular cancer |
| Will radioactive iodine work? | It helps if the tumour takes up iodine; many PDTCs take up less than usual |
| Do I need tablets for life? | Yes, thyroid hormone replacement is lifelong after total thyroidectomy |
| Is it inherited? | Usually not |
| Can it be cured? | Yes, especially when found early and completely removed |
| Will I need a feeding tube or tracheostomy? | Rarely; only when the cancer has invaded the gullet or windpipe extensively |
| Can I have children after treatment? | Usually yes, but pregnancy is generally delayed for 6-12 months after radioactive iodine |
| What if it spreads? | Targeted tablets can control the disease, often for long periods |
12. Questions to ask your care team
- Was the cancer completely removed?
- Has it spread outside the thyroid or to lymph nodes?
- Will radioactive iodine be useful for me?
- Do I need external radiotherapy?
- Has the tumour been tested for BRAF, RET or NTRK changes?
- How often will I have scans and blood tests?
Resources
- Asioli, S. et al. (2010) ‘Poorly differentiated carcinoma of the thyroid: validation of the Turin proposal and analysis of IMP3 expression’, Modern Pathology, 23(9), pp. 1269-1278.
- Kim, J.Y. et al. (2024) ‘Prognosis of poorly differentiated thyroid carcinoma: a systematic review and meta-analysis’, Endocrinology and Metabolism, 39(4), pp. 590-602.
- Tong, J. et al. (2022) ‘Poorly differentiated thyroid carcinoma: a clinician’s perspective’, European Thyroid Journal, 11(2), e220021.
- Xu, B. and Ghossein, R. (2020) ‘Poorly differentiated thyroid carcinoma’, Seminars in Diagnostic Pathology, 37(5), pp. 243-247.
- National Cancer Institute (2026) Thyroid Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/thyroid/hp/thyroid-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.